Lu Nelson, Xu Yunling, Yue Lilly Q
a Food and Drug Administration, Center for Device and Radiological Health, U.S ., Silver Spring , MD , USA.
J Biopharm Stat. 2019;29(4):580-591. doi: 10.1080/10543406.2019.1632880. Epub 2019 Jun 29.
Observational (non-randomized) comparative studies have been adopted in the pre-market safety/effectiveness evaluation of medical devices. There has been an increased interest in utilizing this design with the growing available real-world data. However, in such studies, biases that are introduced in every stage and aspect of study need to be addressed. Otherwise, the objectivity of study design and validity of study results will be compromised. In this paper, challenges and opportunities are discussed from the regulatory perspective. Considerations and good statistical practice to mitigate the potential bias are presented.
观察性(非随机)比较研究已被应用于医疗器械上市前的安全性/有效性评估。随着可获得的真实世界数据不断增加,人们对采用这种设计的兴趣也日益浓厚。然而,在这类研究中,研究各个阶段和方面所引入的偏差都需要加以解决。否则,研究设计的客观性和研究结果的有效性将受到损害。本文从监管角度讨论了挑战与机遇。还提出了减轻潜在偏差的注意事项和良好的统计实践方法。